The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
Donald A. Richards
No relevant relationships to disclose
Fadi S. Braiteh
No relevant relationships to disclose
Stephen Patrick Anthony
No relevant relationships to disclose
Jeff Edenfield
No relevant relationships to disclose
Beth A. Hellerstedt
No relevant relationships to disclose
Robert N. Raju
No relevant relationships to disclose
Paul Conkling
No relevant relationships to disclose
David A. Smith
No relevant relationships to disclose
Carlos Becerra
No relevant relationships to disclose
Allen Lee Cohn
No relevant relationships to disclose
Crystal Shereen Denlinger
No relevant relationships to disclose
Lawrence E. Garbo
No relevant relationships to disclose
Hillary H. Wu
No relevant relationships to disclose
Agustin Garcia
No relevant relationships to disclose
Charlotte McDonagh
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
Sasha Frye
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
Samuel V. Agresta
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
Victor M. Moyo
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack